Brokerages expect Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) to post earnings per share (EPS) of ($0.22) for the current quarter, Zacks reports. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. Adaptimmune Therapeutics reported earnings of ($0.24) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 8.3%. […]
StockNews.com upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) from a sell rating to a hold rating in a research note issued to investors on Wednesday. A number of other equities analysts have also weighed in on ADAP. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a buy rating to a hold rating […]
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Analyst Ratings This is a breakdown of recent ratings and […]
Baillie Gifford & Co. lifted its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,756,352 shares of the biotechnology company’s stock after buying an additional 931,372 shares during […]
Zacks Investment Research downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics […]